Similar articles

• Oligodendroglioma with neurocytic differentiation and characteristic loss of heterozygosity on chromosomes 1p and 19q.

  Vajtai I, Arnold M, Vassella E. Vajtai I, et al. Acta Neuropathol. 2005 Nov;110(5):520-2. doi: 10.1007/s00401-005-1091-8. Epub 2005 Oct 13. Acta Neuropathol. 2005. PMID: 16222523 No abstract available.
• Olig2 is useful in the differential diagnosis of oligodendrogliomas and extraventricular neurocytomas.

  Okada M, Yano H, Hirose Y, Nakayama N, Ohe N, Shinoda J, Iwama T. Okada M, et al. Brain Tumor Pathol. 2011 Apr;28(2):157-61. doi: 10.1007/s10014-011-0017-5. Epub 2011 Feb 11. Brain Tumor Pathol. 2011. PMID: 21312066
• [The oligodendroglioma: the value of histologic and genetic diagnosis in predicting sensitivity to chemotherapy].

  Kros JM. Kros JM. Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1379-85. Ned Tijdschr Geneeskd. 2005. PMID: 15997690 Review. Dutch.
• Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.

  Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Barbashina V, et al. Clin Cancer Res. 2005 Feb 1;11(3):1119-28. Clin Cancer Res. 2005. PMID: 15709179
• Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.

  Sonabend AM, Lesniak MS. Sonabend AM, et al. Expert Rev Neurother. 2005 Nov;5(6 Suppl):S25-32. doi: 10.1586/14737175.5.6.S25. Expert Rev Neurother. 2005. PMID: 16274268 Review.